During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
Murder charges against an Irish nanny, who spent more than two years in prison accused of killing a baby in the USA, have been dropped.
Charities face probe after claims they may have been involved in buying and selling widower's details.
The island of Kivalina in Alaska is quickly disappearing into the ocean, watched by its 400 residents, due to climate change.